Leukemia Research Reports最新文献

{"title":"A rare case of CD38-negative abdominal multiple extramedullary plasmacytoma and literature review","authors":"XS Bao,&nbsp;DH Gong,&nbsp;KG Zhou,&nbsp;W Huang","doi":"10.1016/j.lrr.2024.100493","DOIUrl":"10.1016/j.lrr.2024.100493","url":null,"abstract":"<div><div>Abdominal multiple extramedullary plasmacytoma (EMP) is a rare disease. CD38-negative relapsed/refractory EMP after treatment with daratumumab has never been reported. In 2020, a patient with jaundice was diagnosed with plasmacytoma in another hospital, which progressed one year after receiving multiline therapy. In July 2021, he was admitted to our hospital and showed CD38-pogative plasmacytoma. The patient received 2 cycles of treatment including daratumumab, venetoclax and DCEP chemotherapy and achieved partial remission. However, he developed ascites and eventually died. Our case indicated that multiple EMP has much lower incidence and far worse prognosis than solitary EMP.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100493"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tyrosine kinase inhibitors modulate the expression of peroxiredoxins 1 and 2 in chronic myeloid leukemia cells","authors":"Hiroshi Kazama ,&nbsp;Yan-Hua Wang ,&nbsp;Junji Tanaka","doi":"10.1016/j.lrr.2025.100508","DOIUrl":"10.1016/j.lrr.2025.100508","url":null,"abstract":"<div><div>Chronic myeloid leukemia (CML) is characterized by the presence of the BCR::ABL1 fusion protein with active tyrosine kinase activity. The BCR::ABL1 fusion protein induces the production of reactive oxygen species (ROS). DNA damage caused by ROS is involved in the mechanism of CML progression. Antioxidant systems include peroxiredoxins (PRDXs), which play various roles in hematological malignancies. Although tyrosine kinase inhibitors (TKIs) are known to affect ROS production, their effects on the expression of the antioxidants PRDX1 and PRDX2 remain unclear; thus, we aimed to evaluate the effects of TKIs on the expression of these PRDXs and ROS levels in CML cells. We found that TKIs, such as imatinib, nilotinib, and dasatinib, increased the gene expression of <em>PRDX2</em> in K562 cells; however, only dasatinib increased the cytoplasmic protein expression of PRDX2. Additionally, while TKIs reduced the gene expression of <em>PRDX1</em> in contrast to that of <em>PRDX2</em>, dasatinib increased the cytoplasmic protein expression of PRDX1. This discrepancy was linked to post-translational regulation through SUMOylation in cooperation with dasatinib. Our results suggest that the antioxidants PRDX1 and PRDX2 could serve as potential targets for TKIs in the treatment of CML.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100508"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AL amyloidosis with elevated peripheral blood cell counts – A frequent association with liver involvement. A single-center retrospective study","authors":"Mateusz Ziarkiewicz ,&nbsp;Justyna Szczygieł ,&nbsp;Marta Legatowicz-Koprowska ,&nbsp;Joanna Drozd-Sokołowska ,&nbsp;Piotr Boguradzki ,&nbsp;Krzysztof Jamroziak ,&nbsp;Grzegorz Basak","doi":"10.1016/j.lrr.2025.100509","DOIUrl":"10.1016/j.lrr.2025.100509","url":null,"abstract":"<div><h3>Background</h3><div>AL amyloidosis is a systemic protein misfolding disorder characterized by organ deposition of monoclonal immunoglobulin fragments, with insidious onset and progressive course. The plasma cell clone in the bone marrow is relatively small and typically does not impair hematopoiesis, in contrast to multiple myeloma. Herein we present a novel observation of increased thrombocyte, leukocyte and erythrocyte counts in a subset of AL amyloidosis patients.</div></div><div><h3>Material and Methods</h3><div>We performed a retrospective analysis of medical records of all consecutive patients diagnosed with AL amyloidosis at the Medical University of Warsaw in years 2001–2022, which included clinical, pathological and laboratory data, as well as treatment protocols and outcomes.</div></div><div><h3>Results</h3><div>Twenty-three patients out of 124 (18.4 %) included had elevated blood counts: 17 (13.6 %) had leukocytosis with neutrophilia, 7 (5.6 %) had thrombocytosis, whereas 2 (1.6 %) had erythrocytosis. In comparison to the remaining AL population this subgroup was characterized by younger age (median 57 vs 62 years, <em>p</em> = 0.018), higher frequency of hepatomegaly (42.9 % vs.14.7 %, <em>p</em> = 0.004), higher median alkaline phosphatase concentration (129 U/L vs 93 U/L, <em>p</em> = 0.006) and more frequent hepatic amyloidosis (34.8 % vs 10.3 %, <em>p</em> = 0.003). None of the patients had definite features of a myeloproliferative neoplasm, although genetic testing was available in 5 out of 9 cases with thrombocytosis or erythrocytosis. There were no significant differences in terms of survival between patients with elevated cell counts and non-polycythemic patients (median overall survival 2.9 vs 6.6 years, <em>p</em> = 0.51, median event-free survival 0.7 vs 1.8 years, <em>p</em> = 0.29, respectively).</div></div><div><h3>Conclusions</h3><div>Elevated peripheral blood counts in a subset of patients with AL amyloidosis constitute a rare but significant phenomenon and appear to be associated with frequent hepatic involvement. We hypothesize that cytokine deregulation and hyposplenism may belong to its pathomechanisms.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100509"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143843498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review","authors":"Alaa Eldein Yahia ,&nbsp;Ibrahim Motabi ,&nbsp;Abdullah A. Alsakkaf ,&nbsp;Kamal Alzahrani ,&nbsp;Laila M. Alsuhaibani ,&nbsp;Bilal Albtoosh ,&nbsp;Abdullah Khaled AlBathi ,&nbsp;Abdullah M. Alrajhi","doi":"10.1016/j.lrr.2025.100506","DOIUrl":"10.1016/j.lrr.2025.100506","url":null,"abstract":"<div><div>Acute lymphoblastic leukemia (ALL) represents only 20 % of adult acute leukemias, while Lymphoblastic lymphoma is even rarer, accounting for 2 % of adult non-Hodgkin lymphomas. T-acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) are neoplasms characterized by the presence of immature T-cell precursors or lymphoblasts. Relapsed T-ALL or LBL is associated with a very poor prognosis, necessitating the exploration of novel therapeutic approaches. This case report describes the use of Venetoclax in combination with Cladribine, Idarubicin, and Cytarabine (CLIA) as salvage therapy for relapsed T-ALL/T-LBL. The treatment regimen resulted in remission and negative minimal residual disease. However, it was accompanied by delayed count recovery, febrile neutropenia, and Central Line-Associated Bloodstream Infection. The management of central nervous system involvement was challenging due to low platelet counts requiring transfusion support. The findings highlight the need for further investigation into the efficacy and optimal therapeutic regimen for relapsed T-ALL/T-LBL. Additionally, the case emphasizes the importance of early salvage therapy and potentially consolidative hematopoietic stem cell transplantation for improved survival outcomes in relapsed T-ALL/T-LBL patients.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100506"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective claims data analysis of ASCT characteristics and costs for working-age, multiple myeloma patients in the US, 2017–2019","authors":"Whanhui Chi ,&nbsp;Juhyeon Song ,&nbsp;Tyler J. Varisco","doi":"10.1016/j.lrr.2024.100496","DOIUrl":"10.1016/j.lrr.2024.100496","url":null,"abstract":"<div><div>Multiple myeloma (MM) is a rare hematologic malignancy with a 5-year survival rate of 52 %. For transplant-eligible MM patients, high-dose chemotherapy followed by autologous stem cell transplant (ASCT) is recommended. Given the complexities of the ASCT procedure, understanding patient-specific factors and their impact on treatment decisions is essential.</div><div>Our study examines patient characteristics and patterns of health resource utilization associated with ASCT receipt in patients with MM.</div><div>This retrospective study used the Merative™ MarketScan® database from 2017 to 2019 to analyze working-aged adults (18–65 years) with MM. We categorized 643 ASCT recipients by demographic characteristics (age, sex, region, employment status, year of ASCT procedure) and clinical factors (Charlson Comorbidity Index score). We assessed health resource utilization, focusing on ASCT-related costs, including total payments and hospitalization duration. Descriptive statistics were calculated for all variables, with means, medians, standard deviations for continuous variables, and frequencies for categorical variables. Pearson correlation assessed the relationship between total payment and hospitalization duration.</div><div>Over 80 % of patients were over 50, highlighting the need for age-specific clinical strategies. Most patients had CCI scores of 2–4, indicating a moderate comorbidity burden. The mean hospitalization duration was 21.71 days, with average ASCT costs totaling $166,235.99. The correlation coefficient of 0.21 indicated that total payments also increase as the number of hospitalization days increases.</div><div>These findings highlight the need for tailored care approaches and resource allocation in ASCT, informing future research and clinical decision-making.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100496"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Experience of a rare case of primary acute mast cell leukemia","authors":"Zhijuan Pan,&nbsp;Ying Zhang,&nbsp;Yanru Guo,&nbsp;Jiajia Sun,&nbsp;Xinlei Guo,&nbsp;Zhiping Guo","doi":"10.1016/j.lrr.2025.100510","DOIUrl":"10.1016/j.lrr.2025.100510","url":null,"abstract":"<div><h3>Backgrounds</h3><div>Mast cell leukemia (MCL) is a rare and aggressive form of systemic mastocytosis with a poor prognosis. Understanding the different therapeutic responses to corticosteroids in MCL is crucial for improving patient outcomes.</div></div><div><h3>Case presentation</h3><div>We present a case of a 74-year-old Chinese female with primary acute MCL who exhibited different responses to dexamethasone and methylprednisolone. She was admitted with persistent fever, dyspnea, severe fatigue, and bone pain, alongside splenomegaly and cytopenia. Diagnosis was confirmed through marrow aspirate analysis, chemical staining, flow cytometry, and biopsy, revealing atypical mast cells positive for CD117, CD9, CD81, CD33, CD13, CD4, and partially for CD56, but negative for CD2 and CD25. Next-generation sequencing identified heterozygous mutations in <em>NRAS, DNMT3A</em>, and <em>TP5</em>3, with no <em>KIT</em> mutations. Initial treatment included corticosteroids and dasatinib. The patient showed a partial response to dexamethasone but significant improvement with methylprednisolone. Upon reintroduction of dexamethasone, symptoms recurred, which improved again after resuming methylprednisolone. The patient survived for three months post-diagnosis.</div></div><div><h3>Conclusion</h3><div>This case highlights the potential efficacy of methylprednisolone over dexamethasone in MCL treatment. This case underscores the importance of personalized treatment approaches in MCL, considering the distinct genetic profile and differential therapeutic responses to corticosteroids. Further research is needed to elucidate the mechanisms underlying these responses and to optimize treatment strategies for MCL.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100510"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-coding RNAs: Emerging contributors to chemoresistance in chronic myeloid leukemia","authors":"Laya Ghadyani nejhad ,&nbsp;Mahsa Sohani ,&nbsp;Nasrin Alizad Ghandforoush ,&nbsp;Mohsen Nikbakht ,&nbsp;Saeed Mohammadi ,&nbsp;Mohammad Vaezi ,&nbsp;Shahrbano Rostami ,&nbsp;Bahram Chahardouli","doi":"10.1016/j.lrr.2025.100513","DOIUrl":"10.1016/j.lrr.2025.100513","url":null,"abstract":"<div><div>Chronic myeloid leukemia (CML), is a myeloproliferative disease characterized by unregulated growth of blood forming cells in bone marrow and blood. The t(9;22)(q34;q11.2) translocation, which results in the formation of a hyperactive tyrosine kinase (<em>BCR-ABL</em>), is a hallmark of this disorder. Tyrosine kinase inhibitors such as imatinib has shown a great promise in reduction of CML cells. However, development of resistance to tyrosine kinase inhibitors has raised a great clinical concern about their future applications. Recently, non-coding RNAs, have shown to play significant regulatory roles in development of chemoresistance in CML cells. Discovering the underlying mechanisms of these non-coding RNAs might provide new opportunities for treating chemo-resistant forms of CML. These non-coding RNAs could be considered valuable therapeutic targets if they are found to play a role in the development of chemoresistance in CML cells. We mentioned the identified non-coding RNAs in development of chemoresistance in CML cells.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100513"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143947518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When the mask slips: A peripheral T-cell lymphoma disguised as lupus with myelofibrosis in a patient with May-Hegglin syndrome","authors":"V Da Silva Constante ,&nbsp;H Couvert ,&nbsp;A Wolfromm ,&nbsp;M Ilzkovitz","doi":"10.1016/j.lrr.2024.100498","DOIUrl":"10.1016/j.lrr.2024.100498","url":null,"abstract":"<div><div>We describe the case of a female patient with May-Hegglin syndrome who developed peripheral T-cell lymphoma not otherwise specified. The patient presents with systemic lupus erythematous phenotype and myelofibrosis secondary to T-cell lymphoma. Peripheral T-cell lymphoma not otherwise specified, represents 25 % of all peripheral T-cell lymphoma. Its diagnosis remains challenging due to the polymorphous clinical presentation and pathological heterogeneity. Myelofibrosis associated with malignant lymphomas is rare and peripheral T-cell lymphoma is even rarer. To our knowledge, this is the first case to describe an association between May-Hegglin syndrome and a peripheral T-cell lymphoma.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100498"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting menin for precision therapy in high-risk acute myeloid leukemia","authors":"Abdur Jamil ,&nbsp;Zaheer Qureshi ,&nbsp;Zain Mary El-amir ,&nbsp;Gillian Kupakuwana-Suk ,&nbsp;Hamzah Akram ,&nbsp;Mohsin Ahmad ,&nbsp;Eric Huselton","doi":"10.1016/j.lrr.2024.100495","DOIUrl":"10.1016/j.lrr.2024.100495","url":null,"abstract":"<div><h3>Objective</h3><div>This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways.</div></div><div><h3>Summary</h3><div>The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100495"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Rechallenge with gilteritinib after acute pancreatitis in FLT3-positive AML","authors":"Taner TAN ,&nbsp;Genco Gençdal ,&nbsp;Ümit Barbaros Üre ,&nbsp;Olga Meltem AKAY","doi":"10.1016/j.lrr.2025.100503","DOIUrl":"10.1016/j.lrr.2025.100503","url":null,"abstract":"","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100503"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}